Nasopharyngeal activation of STING pathway
protects from SARs-CoV-2 and influenza in animal models
HOUSTON, July 30,
2024 /PRNewswire/ -- AuraVax Therapeutics, Inc,
recognized its academic collaborators at the University of Houston on publication of their
pre-clinical research demonstrating that a single dose intranasal
NanoSTING protects against SARS-CoV-2 and influenza in hamsters and
mice. NanoSTING is a formulation of 2′3′ cyclic GMP–AMP (cGAMP) in
lipid nanoparticles designed for efficient uptake across mucosa to
activate the stimulator of interferon genes (STING) pathway. The
results show that NanoSTING rapidly and efficiently activates the
innate immune system. The research benefits AuraVax's approach
using NanoSTING to treat and prevent viral infections.
"An intranasal nanoparticle STING agonist protects against
respiratory viruses in animal models," was published in Nature
Communications on 18 July 2024. The
senior author is Dr. Navin
Varadarajan at the University of
Houston and Chief Scientific Officer of AuraVax. It was
co-authored with collaborators at the Institute for Antiviral
Research at Utah State University.
"These data highlight the safety and efficacy of intranasal
NanoSTING to establish a loco-regional immune response against two
important seasonal respiratory viruses," said Joseph Sullivan, CEO of AuraVax. "This research
demonstrates the therapeutic potential of NanoSTING to treat and
prevent viral infections as well as interrupt viral spread. This
host-directed therapeutic is agnostic to viral etiology and appears
unaffected by mutation escape."
About AuraVax
AuraVax Therapeutics, Inc. (AuraVax) is a privately held
biotechnology company commercializing the NanoSTING platform for
the treatment and prevention of multiple respiratory infections.
Intranasal NanoSTING is a broad-acting, host-directed immunotherapy
that safely targets the STING pathway activate innate immunity
against respiratory pathogens and disrupt host-to-host
transmission.
For more information about AuraVax, please visit:
https://www.auravax.com
For additional information about AuraVax, contact Joseph Sullivan at
jsullivan@auravax.com
+1 267-421-9792
View original
content:https://www.prnewswire.com/news-releases/auravax-recognizes-the-university-of-houston-for-publication-on-intranasal-nanosting-a-broad-spectrum-host-directed-therapeutic-for-respiratory-viruses-302210161.html
SOURCE AuraVax Therapeutics Inc.